© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
editorials |
Extensive-stage small-cell lung cancer—moving beyond response rate?
Christie Hospital NHS Foundation Trust, Manchester, UK
* (E-mail: paul.lorigan@manchester.ac.uk)
| The first 10% of the full text of this article appears below. |
With the notable exception of prophylactic cranial irradiation (PCI), there has been little real progress in the management of extensive-stage small-cell lung cancer (ED SCLC) over the last 20 years, despite the evaluation of a number of agents that have proven efficacy in other tumor types. This disappointing outcome has come at a significant cost, both in terms of number of patients enrolled in essentially negative trials and the expense of carrying out these studies. There are two obvious conclusions—we need new treatment approaches and we need to design studies capable of predicting at an earlier stage the likely outcome.
Response